We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-10.34%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.07B
AUM Growth
-$1.75B
(-62%)
Cap. Flow
-$771M
Cap. Flow
% of AUM
-72.36%
Top 10 Holdings %
Top 10 Hldgs %
79.25%
Holding
36
New
4
Increased
1
Reduced
17
Closed
11
Avg Time Held Equity + Options
8.8
quarters
Top 10 Avg Time Held Equity + Options
3.3
quarters
Top 20 Avg Time Held Equity + Options
6.2
quarters
Avg Time Held Equity only
9.3
quarters
Top 10 Avg Time Held Equity only
3.1
quarters
Top 20 Avg Time Held Equity only
7.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$42.6M |
| 2 |
Merck
MRK
|
+$39.7M |
| 3 |
UnitedHealth
UNH
|
+$38.2M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.7M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$121M |
| 2 |
Humana
HUM
|
+$106M |
| 3 |
Baxter International
BAX
|
+$87.9M |
| 4 |
CVS Health
CVS
|
+$78.7M |
| 5 |
PTC Therapeutics
PTCT
|
+$76.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.39% |
| 2 | Miscellaneous | 32.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Cigna
CI
$74.7B
| – | – |
-200,000
| Closed | -$65.8M | – |
|
27
Genmab
GMAB
$22.5B
| – | – |
-50,000
| Closed | -$979K | – |
|
28
Structure Therapeutics
GPCR
$1.59B
| – | – |
-300,000
| Closed | -$5.19M | – |
|
29
Ionis Pharmaceuticals
IONS
$7.04B
| – | – |
-725,000
| Closed | -$21.9M | – |
|
30
MoonLake Immunotherapeutics
MLTX
$886M
| – | – |
-441,000
| Closed | -$17.2M | – |
|
31
CALL
Pfizer
PFE
$162B
| – | – |
-6,800,000
| Closed | -$172M | – |
|
|
32
PTC Therapeutics
PTCT
$5B
| – | – |
-1,500,000
| Closed | -$76.4M | – |
|
33
Qiagen
QGEN
$9.38B
| – | – |
-1,400,000
| Closed | -$56.2M | – |
|
34
Sarepta Therapeutics
SRPT
$1.74B
| – | – |
-800,000
| Closed | -$51.1M | – |
|
35
10x Genomics
TXG
$9.35B
| – | – |
-1,000,000
| Closed | -$8.73M | – |
|
36
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| – | – |
-2,000,000
| Closed | -$162M | – |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Camber Capital Management held 36 positions worth $1.07B, down 62% from $2.81B the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Camber Capital Management withdrew a net $771M in Q2 2025, closing 11 positions and reducing 17 holdings. Its most notable exit was PTC Therapeutics, an estimated $76.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 57% a quarter earlier, followed by Miscellaneous.
Against the trend, Camber Capital Management opened a new position in Icon worth $43.6M.
- Camber Capital Management's largest Q2 2025 buy was Icon: 300,000 shares worth $43.6M.
- Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2025, an estimated $5.89M increase.
- Camber Capital Management's biggest Q2 2025 reduction was Zimmer Biomet, cutting an estimated $121M.
- Camber Capital Management fully exited PTC Therapeutics in Q2 2025, selling an estimated $76.4M.
- Camber Capital Management's ten largest holdings make up 79% of its $1.07B portfolio in Q2 2025.
- Camber Capital Management opened 4 new positions and closed 11 in Q2 2025.
- Camber Capital Management's portfolio value fell 62% quarter-over-quarter to $1.07B.
Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.